PEBC Pharmacy Practice Management Flashcards

A pharmacist receives a faxed prescription for hydromorphone 8 mg tablets, quantity 120, from a physician's office. The prescription is for a patient with documented cancer pain. Under the NAPRA Model Standards and provincial regulations, which condition would make this prescription INVALID even if all other elements are present?

Answer: Hydromorphone 8 mg exceeds the threshold that permits fax transmission for narcotic prescriptions in most provinces

Under the Controlled Drugs and Substances Act (CDSA) and provincial regulations, Schedule I narcotics (including hydromorphone) generally cannot be dispensed on a faxed prescription — they require a written original signed by the prescriber. Hydromorphone 8 mg is a Schedule I narcotic, and the fax is therefore not a valid prescription instrument for this drug, regardless of quantity or clinical justification. The DEA number is a U.S. Drug Enforcement Administration identifier irrelevant to Canadian practice, and the 30-day supply restriction is a dispensing limit, not a prescription validity criterion.

A pharmacy corporation owns 12 outlets across two provinces. The corporation's head office, located in Province A, instructs all pharmacists to substitute a specific house-brand generic for every eligible brand-name product to maximize rebate revenue — without pharmacist-level review of individual patient suitability. Which professional and regulatory principle is MOST directly violated?

Answer: The requirement that each dispensing pharmacist exercise independent professional judgment for each patient encounter

Corporate-mandated automatic substitution without individual pharmacist review violates the foundational principle that a pharmacist must exercise independent professional judgment for every patient encounter. Pharmacy legislation across provinces protects this principle specifically to prevent corporate interests from overriding clinical decision-making. While therapeutic substitution rules (answer A) are relevant, the scenario describes generic substitution, not therapeutic substitution — and the core issue is the removal of pharmacist discretion. Ownership restrictions (answer C) and public posting requirements (answer D) are real but are not the most directly violated principle here.

A pharmacist is completing a MedsCheck for a patient on warfarin who also takes St. John's Wort purchased at a health food store. The patient's INR has been subtherapeutic for three consecutive months. The pharmacist documents the interaction and counsels the patient, but the patient refuses to discontinue the supplement. The pharmacist does NOT notify the prescribing physician. Six weeks later, the patient suffers a thromboembolic event. Under pharmacy negligence law, the pharmacist's liability exposure is BEST characterized as:

Answer: Significant, because the standard of care likely required proactive communication to the prescriber despite patient refusal

While documenting and counselling are necessary components of the standard of care, they are not sufficient when a patient refuses an intervention that is clinically urgent and where a third party (the prescriber) could alter the treatment plan. Courts and pharmacy regulatory bodies have held that pharmacists have a duty to proactively communicate with prescribers when patient safety is at risk and the patient's refusal prevents resolution. Patient refusal does not extinguish the pharmacist's independent duty to the patient's wellbeing, and assumption of risk is a defence that does not fully transfer liability when the pharmacist had available means to mitigate harm (i.e., contacting the physician). Manufacturers are not liable for drug-supplement interaction failures at the dispensing level.

A provincial government introduces a new policy requiring pharmacists to perform Medication Reviews for all patients on five or more chronic medications, billable to the provincial drug plan at $75 per review per year. A chain pharmacy instructs pharmacists to complete these reviews in under 8 minutes to maximize throughput. A pharmacist completes 40 such reviews in a single shift, averaging 6 minutes each, and bills the provincial plan for all 40. Which regulatory risk is MOST significant?

Answer: Potential fraud against the provincial drug plan if the billed reviews do not meet the service definition's minimum standards

Billing for a professional cognitive service that does not meet the provincial drug plan's service definition — which typically specifies a minimum standard of care, documentation, and often encounter duration — constitutes fraudulent billing. Provincial drug plans have audit mechanisms and can demand repayment, impose penalties, and refer matters to the College. The pharmacist and corporation are exposed to both regulatory (College) and civil/criminal (fraud) consequences. Physical space standards (answer A) are not relevant to encounter duration. Labour regulations (answer C) govern employment, not billing validity. NAPRA does not set a specific 20-minute minimum for MedsChecks (answer D) — that is a distractor conflating NAPRA guidance with provincial billing rules.

A pharmacist working in a remote First Nations community operates under a collaborative practice agreement (CPA) that permits independent prescribing for a defined list of conditions. A patient presents with symptoms consistent with uncomplicated urinary tract infection (UTI). The pharmacist initiates nitrofurantoin therapy under the CPA. The patient later reports she is 10 weeks pregnant. Which of the following BEST describes the pharmacist's liability and appropriate retrospective action?

Answer: Liability is shared but the pharmacist should immediately reassess the prescription, consult current guidelines on nitrofurantoin in early pregnancy, and document the clinical decision and communication to the supervising physician

Nitrofurantoin is generally considered acceptable in the first and second trimesters but is avoided in the third trimester (near term) due to risk of neonatal hemolytic anemia. At 10 weeks, the prescription may be clinically appropriate, but the pharmacist must reassess using current pregnancy-specific guidelines, communicate with the supervising physician per CPA requirements, and document thoroughly. The pharmacist's liability is not zero (they must exercise judgment even under a CPA) nor is it fully equivalent to physician liability (CPAs create shared accountability structures). Blanket contraindication of all medications in the first trimester (answer D) is clinically incorrect and dangerous advice.

A pharmacy receives a request from a police officer who presents a badge and states they need the dispensing history for a specific patient as part of an active drug trafficking investigation. The officer does not have a court order or search warrant but verbally states one is 'being processed.' Under PIPEDA and provincial health information protection legislation, the pharmacist's CORRECT response is:

Answer: Decline to release records without a valid court order, search warrant, or other lawful authority, and document the request and refusal

Under PIPEDA and provincial health information protection acts (e.g., PHIPA in Ontario, HIA in Alberta), health information custodians may only disclose personal health information to law enforcement with lawful authority — typically a court order, search warrant, or statutory provision explicitly permitting warrantless disclosure. A verbal claim that a warrant is 'being processed' is not lawful authority. Releasing records without proper legal authority exposes the pharmacist and pharmacy to significant regulatory and civil liability. PIPEDA does not specify a 90-day disclosure limit (answer B — a distractor). Contacting the College (answer D) is a reasonable concurrent step but is not the primary obligation, and the College does not authorize disclosures. The pharmacist should document the request and the refusal thoroughly.